Abstract: The invention provides methods and kits for treatment of pain, inflammation, neuronal or vascular injury and the use of biomarkers for the assessment of the biological activity or disease state. In one embodiment, the kit comprises a biomembrane sealing agent, such as PEG, a bioactive agent, such as a magnesium compound, and an assay for measuring a biomarker. The biomarker is measured pre-, mid- and post-treatment, and results of the measurements are compared to evaluate the treatment, treatment regimen and outcomes.
Abstract: The present invention provides an enhanced gelling agent composition comprising a mixture of an anionic surfactant and a coupling agent. The invention also describes compositions in gel form comprising: (a) a solvent selected from the group consisting of polar solvents, non-polar solvents and combinations thereof; and (b) a gelling agent in an amount sufficient to impart gelation to the composition, the gelling agent being a mixture comprising an anionic surfactant and a coupling agent. The gels of the invention may be substantially anhydrous or may optionally contain water as part of the formulation.
Abstract: The present invention provides compositions and methods for treating disorders and diseases by delivery of LFA-1 antagonists to the gastrointestinal system. Methods include delivery of LFA-1 antagonists to effect localized treatment.
Abstract: The present invention relates to compositions and methods for treating neurodegenerative diseases. In some embodiments, the present invention provides compositions for treating and preventing presbycusis.
Abstract: An aluminum salt-containing resin powder of the present invention includes: at lest one matrix resin component selected from regenerated collagen, polyvinyl alcohol and carboxymethyl cellulose; and an aluminum salt. The aluminum salt is chemically bonded to the matrix resin component, and the resultant is powdered. A resin composition of the present invention includes 0.1 wt % or more and 80 wt % or less of the aluminum salt-containing resin powder and 20 wt % or more and 99.9 wt % or less of a resin other than the aluminum salt-containing resin. Thus, the present invention provides an aluminum salt-containing resin powder having a high phosphorus adsorption property, a high antibacterial property and a high antifungal property, and a resin composition containing the aluminum salt-containing resin powder.
Abstract: Helicobacter pylori strains are indigenous to each human host and infect and colonize in the stomach of the host, and they are also known to be involved in diseases of the upper gastrointestinal tracts, among others. The present invention provides an economical method for inhibiting the proliferation and migration of Helicobacter pylori strains without being concerned about emergence of resistant bacteria or side effects due to drugs traditionally used to remove Helicobacter pylori strains, as well as a beverage or food utilizing such method, by selecting from among mineral-rich waters obtained from deep sea water, and by ingesting, a water or waters capable of inhibiting the proliferation and migration of Helicobacter pylori strains that are indigenous to the host and infecting and colonized in the stomach of the host.
Type:
Application
Filed:
September 25, 2006
Publication date:
September 24, 2009
Inventors:
Hiroaki Takeuchi, Yoshinari Ikegami, Takeshi Yasukawa, Koji Nakagawa
Abstract: An exercise-enhancing food tablet, preferably a hard or chewable candy or mint, is disclosed for enhancing exercise and physical fitness when ingested before, during, and/or after exercise. The edible tablet includes a mixture of carbohydrate and protein, the protein portion being between 20% and 40% of the mixture by weight, and preferably between 25% and 33% of the mixture by weight. The protein portion is preferably whey protein, but can be any combination of whey protein, soy protein, and pea protein. The carbohydrate portion of the mixture is preferably 85% dextrose and 15% fructose, but can be any combination of dextrose, maltodextrin, fructose, and sucrose. In preferred embodiments, sodium, potassium, magnesium, vitamin C, and/or caffeine are also included. The tablets can also include a flavoring, such as spearmint, peppermint, or fruit flavoring. In preferred embodiments the tablets weigh substantially 2 grams, and an adult serving is eight tablets.
Abstract: The invention relates to a method of activating a photosensitizer, wherein for the photosensitizer nanoparticles of a catalyst capable of catalyzing the production of active oxygen (1) is selected, which is further subjected to irradiation by light (5). Preferably, heterocrystal minerals are used as a source of nanoparticles. Preferably, the photosensitizer is combined with a liquid (3), to which a suitable amount of oxygen gas (4) is added. Still preferably, the photosensitizer is chemically coupled to a DNA-molecule and a suitable anti-metabolic agent. The invention further relates to a method for treating a health disorder using activated photosensitizer provided in nanoparticle form, whereby the activated nanoparticle photosensitizer is administered to a recipient (7).
Abstract: Disclosed is a system that prevents the development of infection and biofilm establishment in medical devices in general, and in particular Urinary Tract Infections (UTI), including Catheter-Associated Urinary Tract Infections (CAUTI). The system comprises of a medical device (such as a catheter) and an antimicrobial composition containing an antimicrobial compound. A medical device delivers the composition both to the inside and/or outside portions of the device, as well as to the inside of the bladder itself and to the urethra. Reduction or elimination of the infection may be accomplished by irrigating the medical device, bathing the bladder, or irrigating the bladder with the composition.
Type:
Application
Filed:
September 21, 2006
Publication date:
September 3, 2009
Inventors:
Ramin Najafi, Mansour Bassiri, Lu Wang, Behzad Khosrovi
Abstract: This invention is based on the identification of the role played by the receptor mX on certain insects through the behavior evinced in the taste sensory reactions of these insects. The invention addresses the use of the modulators on the mX receptor, such as L-canavanine and/or a mix of arginine and calcium and/or N-methyl-L-arginine (NMA) which are used to prepare a compound with repellent or attractive qualities with regard to certain insects. The invention also concerns the use of an mX insect receptor as a target for the identification of repellent substances regarding at least some insects.
Type:
Application
Filed:
May 14, 2007
Publication date:
September 3, 2009
Applicants:
Centre National De La Recherche Scinetifique, Universite De Montpellier I
Inventors:
Yves Grau, Christian Mitri, Marie-Laure Parmentler
Abstract: The present invention relates to compositions and their use for the treatment of human skin, particularly facial skin, to alleviate the symptoms of cosmetic or determatologic skin conditions. The invention relates to compositions for treating and ameliorating skin conditions including acne, rosacea and wrinkling caused by photodamage or conditions related to aging, hormonal imbalances, hyper-pigmentation, melasma, keratosis or the like. The invention can also be used to treat conditions of the scalp such as dandruff. The present invention also relates to compositions that can be used to remove biofilms from contact lenses. More particularly, this invention relates to a composition comprising (a) one or more metasilicate; (b) one or more carbonate; (c) one or more glyconate; and (d) one or more sulfate. The composition may also contain (e) salts, e.g., sea salts and other additives or active agents.
Abstract: Glycopyrronium bromide, derivatives and/or isomers thereof in combination with one or more active substances selected from a list of substances as recited in the claims and/or in the form of a W/Si emulsion, an O/W gel, a soap gel stick, and/or a surfactant-containing cleansing formula, and corresponding cosmetic preparations, in particular deodorant/antiperspirant preparations.
Type:
Application
Filed:
December 27, 2005
Publication date:
August 20, 2009
Applicant:
BEIERSDORF AG
Inventors:
Michael Woehrmann, Lara Terstegen, Stefan Biel, Thomas Raschke, Svenja-Kathrin Cerv, Werner Zilz, Sven Untiedt, Thomas Nuebel, Uwe Schoenrock, Heiner Max, Helga Biergiesser, Yvonne Eckhard, Heike Miertsch, Heike Foelster, Cornelia Meier-Zimmerer, Bernd Traupe, Inge Kruse
Abstract: A controlled release pharmaceutical composition comprising a strontium salt. The invention also relates to the use of a strontium salt for treating a male suffering from diseases and conditions affecting metabolism and/or structural integrity of cartilage and/or bone. The invention also relates to the use of a strontium-containing compound for preventing a cartilage and/or bone condition in a subject, and for the treatment and/or prophylaxis of secondary osteoporosis.
Type:
Application
Filed:
December 22, 2008
Publication date:
July 30, 2009
Inventors:
Christian Hansen, Henrik Nilsson, Jens E.T. Andersen, Stephan Christgau
Abstract: The invention provides compositions, methods and devices relating to a silaceous oxide that generates a reduced heat of hydration upon contact with blood. By reducing the heat of hydration, the compositions provide a hemostatic agent that attenuates a tissue burning side effect of conventional hemostatic agents without adversely affecting the wound healing properties of the composition.
Type:
Application
Filed:
January 12, 2009
Publication date:
July 23, 2009
Inventors:
Galen D. Stucky, Todd A. Ostomel, Qihui Shi, Peter K. Stoimenov, Patricia A. Holden
Abstract: A method of treatment of liver diseases and comorbid diseases is disclosed wherein an oral dose of lipids in an amount effective to trigger the release of cholecystokinin (CCK) into the duodenum to generate a major release of bile phospholipids from remodeled stores of triglycerides (TAG) in the liver, is administered to a patient in need thereof, thereby causing the formation of sequestered and aggregated mixed micelles and vesicles (SAMMVs) in the intestines of the patient which are then eliminated via the bowels of the patient.
Abstract: A method of treating otosclerosis in a human in need thereof by administering a bisphosphonate in a defined dosing schedule. The invention demonstrates an effective response and sustained benefit in the treatment of otosclerosis. Particularly, the method involves administration of a bisphosphonate in a stepped-up dosage amount, e.g., in a dose that is at least one and a half times the recommended dose for osteoporosis. It also includes administration of a time-dependent dose of more than one bisphosphonate, specifically, alternating administration of a first bisphosphonate with a second bisphosphonate. The inventive method further includes intravenous administration of a bisphosphonate, and optionally oral administration of a bisphosphonate.
Abstract: A composition is provided which comprises an acidic component, generally fulvic acid, having a molecular weight not exceeding 20,000 Daltons and a low content of the elements aluminium, mercury, cadmium, chromium and lead. The acidic component is preferably carbohydrate derived and preferably using a wet oxidation process.
Type:
Application
Filed:
April 26, 2007
Publication date:
July 9, 2009
Applicant:
PFEINSMITH S.A. (pty) LTD
Inventors:
Earle John Loxton, Rudolph Johannes Malan, Stefan Coetzee
Abstract: The present invention relates to cosmetic, dermatological, and pharmaceutical compositions that deliver, in an acceptable vehicle or carrier comprising a film former or wax and an effective amount of nanoparticles and one or more pigments and methods for improving the appearance of a biological surface by altering the optical properties of the biological surface. The compositions of the invention enhance color and may be topically applied to the biological surface in an amount effective in improving the aesthetic and natural appearance of the biological surface.
Type:
Application
Filed:
January 8, 2008
Publication date:
July 9, 2009
Applicant:
Avon Products, Inc.
Inventors:
Prithwiraj Maitra, Steven Carlo, Rahul A. Ranade
Abstract: A hydraulic cement for biomedical applications. The cement sets in-situ, hardening when exposed to water to produce nano-dispersed composite of calcium-silicate-hydrate gel mixed with hydroxyapatite. In comparison with prior cements, the composition provides high biocompatibility, high bioactivity and high biomechanical strength, due to the composite structure of the calcium silicate hydrate reinforced with co-precipitated particles of hydroxyapatite. Biocompatibility is also increased due to an absence of aluminum and magnesium in the composition. The cement is suitable for variety of applications, including dental implants, bone fixation, and bone repair.
Abstract: A wipe that includes a bacteriostatic agent that contains cations having an affinity for the negatively charged cell walls of bacteria is provided. The affinity of the bacteriostatic agent for the bacteria allows the wipe to capture bacteria, thereby removing them from a surface and also inhibiting their spread to other surfaces that may contact the wipe. Of particular advantage, the bacteriostatic agent may help protect against the spread or infection of pathogens without the use of chemicals, such as antiseptics or antibiotics. Still further, the wipe of the present invention also contains a solvatochromatic indicator that undergoes a color change in the presence of a broad spectrum of bacteria. Thus, when the wipe captures bacteria, the indicator undergoes a color change that signals to the user that the wipe is functioning properly. The lack of a color change may likewise provide the user with the assurance that the area is generally free of bacteria and clean.
Type:
Application
Filed:
December 13, 2007
Publication date:
June 18, 2009
Applicant:
KIMBERLY-CLARK WORLDWIDE, INC.
Inventors:
Stephanie M. Martin, John Gavin MacDonald, Bao Trong Do
Abstract: Metallo-proteins including but not limited to lactoferrin (LF), transferrin (TF) and ovotransferrin (OTF) (all members of transferrin family), ceruloplasmin (CP) and metallo-thionein (MT) were found to stabilize and enhance the bio-functional activity of tocotrienol (T3), T3 mixtures or derivates. The synergism between MP and T3 also promote the intestinal transfer and the ultimate bio-availability of T3 and T3-derivatives for physiological functions. Such functional synergism includes hypocholesterolemic, anti-thrombotic, antioxidant, anti-athermogenic, anti-inflammatory and immuno-regulatory activities of T3 agents. These T3 compositions are useful as pharmaceuticals, in cosmetics, in foods and as nutritional supplements.
Type:
Application
Filed:
December 3, 2008
Publication date:
June 11, 2009
Applicant:
Naidu LP
Inventors:
A. Satyanarayan Naidu, A.G. Sreus Naidu
Abstract: In certain described embodiments, implantable medical materials comprise a scaffolding material, a liquid organic binder, and entrapped calcium-containing particles. The medical materials can incorporate an osteoinductive factor such as a protein. The scaffolding material can bind the factor. In additional described embodiments, implantable medical materials include an osteoconductive scaffolding material, an incorporated osteoinductive factor, and a biodegradable barrier material effective to delay release of the factor from the scaffolding material. The scaffolding material can bind the factor. Also described a methods for preparing and implanting the described medical materials.
Type:
Application
Filed:
December 4, 2007
Publication date:
June 4, 2009
Applicant:
WARSAW ORTHOPEDIC, INC.
Inventors:
Jeffrey M. Gross, Steve Peckham, Jeffrey Scifert, Jeffrey Badura, Nelson Scarborough, Scott Vickers
Abstract: The use of docosahexaenoic acid in the manufacture of a composition for administration to a pregnant woman for reducing the risk of development of overweight or obesity of the baby in infancy and/or early childhood.
Abstract: Two-phase preparation for temporally gradual administration comprising a) a phase (A) comprising water soluble vitamins and/or the corresponding provitamins, wherein phase (A) does not contain liposoluble vitamins or provitamins corresponding to liposoluble vitamins, b) a phase (B) comprising vitamins and/or the corresponding provitamins, wherein the quantity of liposoluble vitamin compounds is larger than the quantity of water soluble vitamin compounds.
Abstract: A pharmaceutical formulation for treating tinea of feet and hands is disclosed, which is composed of Fructus Gleditsia, Alumen and Borneol. Also disclosed is a cream preparative method of the pharmaceutical formulation, which comprises Fructus Gleditsia is decocted with water, and the decocted liquid is dried under decompression into powder, which is formulated to a cream together with the powders of Alumen and Borneol as well as the respective excipients.
Type:
Application
Filed:
February 12, 2007
Publication date:
May 21, 2009
Applicant:
SHEN ZHEN BEI KE LIAN PHARMACEUTICAL SCI-TECH CO., LTD.
Abstract: The present invention provides macrolide derivatives, which can be used as antibacterial agents. Compounds described herein can be used for treating or preventing conditions caused by or contributed to by gram-positive, gram-negative or anaerobic bacteria, more particularly against, for example, Staphylococci, Streptococci, Enterococci, Haemophilus, Moraxalla spp., Chlamydia spp., Mycoplasm, Legionella spp., Mycobacterium, Helicobacter, Clostridium, Bacteroides, Corynebacterium, Propionibeacterium, Bacillus, Enterobactericeae or any combination thereof. Also provided are processes for preparing compounds described herein, pharmaceutical compositions thereof, and methods of treating bacterial infections.
Abstract: The present invention provides compositions and methods for decreasing photosensitivity induced by photodynamic therapy (PDT). The compositions and methods of the present method employ porphyrin complexing molecules as agents for reducing photosensitivity.
Abstract: The present invention relates to compositions and methods for preventing migraines. The migraine prophylaxis composition is a single dosage form comprising at least one form of elemental magnesium and at least one NSAID. The prophylaxis composition, comprising at least one form of elemental magnesium and a therapeutically effective concentration of acetylsalicylic acid may also provide cardiac protection and prevent cardiovascular diseases.
Abstract: A system and method for treating hoof related diseases, particularly hairy heel warts (papillomatus digital dermatitis), includes an aqueous solution having a metal astringent at a therapeutically effective concentration. The metal astringent includes aluminum, iron, and mixtures thereof. In preferred embodiments, the metal may include a mixture of monomeric and polymeric species. The polymeric species may be in the form of a polymeric concentrate, such as, for example, polyaluminum chloride or polyferric sulfate. Alternatively, the polymeric species may be formed by partially neutralizing a metal salt. The aqueous solution of the metal astringent is applied to a lower leg and hoof area of an animal using any known application technique, including, but not limited to, foot baths, foams and spray applications. In preferred embodiments, the aqueous solution is applied using an automated dispensing system.
Type:
Application
Filed:
October 25, 2007
Publication date:
April 30, 2009
Applicant:
Ecolab, Inc.
Inventors:
Joseph P. Morelli, Jeffrey R. Fernandes
Abstract: This invention relates generally to a method of increasing cytosolic Ca2+ levels in mammalian cells comprising contacting P2X receptor Ca2+ entry channels or any and all other Ca2+ entry channels or mechanisms on the cell with an effective amount of a small molecule, and a composition comprising the small molecule in a delivery system. The invention has broad applicability in the pharmaceutical industry as a method of treating airway diseases (such as cystic fibrosis and asthma), ailments of the lung and airways (such as those caused by common cold pathogens or allergens in allergy), kidney diseases and renal hypertensive disorders (such as polycystic kidney disease and salt-sensitive hypertension syndromes), and endocrine disorders (such as diabetes).
Abstract: The present invention relates to the use of polyunsaturated fatty acids and one or more components which have a beneficial effect on total methionine metabolism selected from the group consisting of vitamin B12 and precursors thereof, vitamin B6 and derivatives thereof, folic acid, zinc and magnesium, in the manufacture of a preparation for improving the action of receptors. This preparation is advantageously applied in patients suffering from Parkinson's disease, Huntington's chorea, epilepsy, schizophrenia, paranoia, depression, sleep disorders, impaired memory function, psychoses, dementia and ADHD.
Type:
Application
Filed:
December 1, 2008
Publication date:
April 23, 2009
Applicant:
N.V. NUTRICIA
Inventors:
Amanda Johanne KILIAAN, Robert Johan Joseph Hageman
Abstract: A method of providing a rapid, broad spectrum bacterial control, and a rapid persistent antiviral control on a surface, and particularly a mammalian skin surface, is disclosed. In the method, a compound or composition capable of lowering skin pH to less than about 4 is applied to the skin, and preferably is allowed to remain on the skin.
Type:
Application
Filed:
December 5, 2005
Publication date:
April 23, 2009
Applicant:
THE DIAL CORPORATION
Inventors:
Timothy J. Taylor, Harry E. Towner, Janice L. Fuls, Bruce R. Cox, George E. Fischler, Priscilla S. Fox, Nancy D. Rodgers, James Dalton
Abstract: The invention relates to medicine, in particular to pharmacology, and is embodied in the form of an agent for limiting neuro-mediator, neuro-endocrine and metabolic disturbances generating the disorders of a central nervous system and functional somatic disorders. The inventive agent is based on a DSIP (delta sleep inducing peptide) or a derivative chemically related thereto and can be used for correcting and preventing functional shifts in a central nervous system and concomitant somatic disorders caused by unfavourable and extreme environmental factors and different pathological conditions of an organism or during the ageing thereof.
Type:
Application
Filed:
August 23, 2006
Publication date:
April 16, 2009
Inventors:
Inesa Ivanovna Mikhaleva, Vadim Tikhonovich Ivanov, Igor Arkadjevich Prudchenko, Boris Olegovich Voitenkov
Abstract: The present invention provides methods and mixtures for treating unilateral vocal fold paralysis (UVFP) and/or enhancing functional recovery of a damaged recurrent laryngeal nerve (RLN). The method of the present invention comprises applying a fibrin glue mixture to a portion of laryngeal muscle. The fibrin glue mixture comprises a growth factor, fibrinogen, aprotinin and divalent calcium ion.
Abstract: Acid-neutralizing agent contains substantial amount of calcium of an acid-neutralizing ability against various acid chemicals substance for humans, animals, agricultural produces, meat and poultry. And the method of producing the same are provided. An environmental friendly high speed and high press scraping treatment is applied to a calcium-containing substance represented by calcium carbonate-containing substances originating from shellfishes, to eliminate heavy metals and other contamination accumulated on the surface. A heating and baking treatment is applied separately to the different said shellfishes and calcium carbonate-containing minerals and charcoal of bamboo to the temperature and maintaining the temperature not less then the decompose point of each calcium component-containing substance, a sufficient time of heating and baking treatment from 3 hours up to 18 hours depend on materials treated.
Abstract: A topical product to protect the skin from free radicals is disclosed in one embodiment of the invention as including a carrier medium for topical application to the skin. A sacrificial material that is compatible with the skin is interspersed with the carrier medium. This sacrificial material may be selected to react with free radicals within the skin. The sacrificial material may be further selected to react with water to produce hydrogen (a powerful antioxidant) and a reaction product that is also compatible with the skin. In this way, both the sacrificial material and the hydrogen will react with free radicals to provide protection against free radicals.
Abstract: Compositions and formulations are provided comprising a growth factor fraction and at least one glucan. Also provided are methods for making the compositions and formulations. Methods of promoting growth in an animal using the compositions and/or formulations are also provided.
Abstract: This invention relates to methods of treating or preventing bone loss by administering to a human or animal subject pyrimidine and pyridine derivatives that inhibit the activity of glycogen synthase kinase 3 (GSK3), to pharmaceutical compositions containing the compounds, and to the use of the compounds and compositions alone or in combination with other pharmaceutically active agents.
Type:
Application
Filed:
December 1, 2008
Publication date:
March 19, 2009
Inventors:
Christina N. Bennett, Kurt D. Hankenson, Stephen D. Harrison, Kenneth A. Longo, Ormond A. MacDougald, Allan S. Wagman
Abstract: Combinations of a polyunsaturated fatty acid and diindolylmethane and pharmaceutical composition containing such combinations. Further provided are combinations including a polyunsaturated fatty acid, diindolylmethane, and folic acid. Also provided are combinations including diindolylmethane and folic acid. Also provided is a method for increasing the number of normal cells and decreasing the number of aberrant cells in a subject having the steps of administering to the subject a combination comprising a polyunsaturated fatty acid and diindolylmethane.
Abstract: The present disclosure relates to novel compositions which provide improved nutritional support for premenopausal and menopausal women and/or relief from systems associated with menopause, as well as prophylactic effects, and methods for using same.
Type:
Application
Filed:
November 14, 2008
Publication date:
March 12, 2009
Applicant:
DRUGTECH CORPORATION
Inventors:
R. Saul Levinson, Marc S. Hermelin, Mitchell I. Kirschner
Abstract: Disclosed are methods and products such as wet wipes and absorbents capable of providing a skin health benefit when utilized in the intended fashion. More specifically, the products described herein comprise an agent, such as a botanical extract, which is capable of increasing the activity of sphingomyelinase according to a Sphingomyelinase Activity Screening Test and/or decreasing the activity of ceramidase according to a Ceramidase Activity Screening Test. By increasing the activity of sphingomyelinase and/or decreasing the activity of ceramidase, the agents in combination with the products described herein are able to maintain or increase the level of ceramides in the skin leading to improved skin health.
Type:
Application
Filed:
October 21, 2008
Publication date:
February 26, 2009
Applicant:
KIMBERLY-CLARK WORLDWIDE, INC.
Inventors:
David W. Koenig, Jamie Joseph Van Gompel
Abstract: A composition comprising at least 5%, by weight, of calcium and at least 5%, by weight, of magnesium wherein the composition is derived from marine algae.
Abstract: A pharmaceutical composition is disclosed in the present invention, which contains a medical material of Triticum aestivum L., a medical material of Glycyrrhizae Radix, and at least one calcium ion source. The pharmaceutical composition of the present invention can be taken by animals so as to improve anxious behaviors of the animals.
Abstract: The present invention is a method to accelerate the coagulation of blood through the application of inorganic materials to the wound of a patient on anticoagulant or platelet blocker therapy. The method comprises contacting such wounds with a substance selected from the group consisting of zeolitic molecular sieves and non-zeolitic molecular sieves, diatomaceous earth, glass powder or fibers, precipitated or fumed silica, kaolin and montmorillonite clays and Ca exchanged permutites.
Abstract: The present invention is the development of haemostatic compositions that use nitrogen containing organic polymers in combination with haemostatic agents to create a gel form. Compositions utilizing the polymers exhibit relatively lower concentrations of haemostatic agents, drawing benefits from such lower concentrations as they limit unwanted side effects of the haemostatic agents. Preferred compositions utilize Poly(N-vinylpyrrolidone), Poly(2-ethyl-2-oxazoline) as thickening agents and ferric sulfate as an active ingredient.
Abstract: In one aspect, the present invention provides methods of determining susceptibility to bone fracture in a mammalian subject, wherein the methods comprise analyzing nucleic acid molecules obtained from the mammalian subject to determine which of the P, p X, and x alleles of the estrogen receptor ? gene are present, wherein the presence of a haplotype comprising the p and x alleles is indicative of an increased susceptibility to bone fracture. The present invention also provides kits for determining susceptibility to bone fracture in a mammalian subject.
Type:
Application
Filed:
April 3, 2008
Publication date:
February 12, 2009
Inventors:
Andreas Gerardus Uitterlinden, Johannes Petrus Maria Van Leeuwen, Huibert Adriaan Pieter Pols
Abstract: The invention relates to oral pharmaceutical compositions which take the form of orally-dispersible tablets containing calcium and, optionally, vitamin D and/or fluorine together with pharmaceutically-acceptable excipients and which can be used for the treatment or prevention of osteoporosis and other diseases characterised by loss of bone mass.
Abstract: Agglomerates comprising calcium-hydrocolloid-composite materials and at least one sugar alcohol, as well of methods for preparing the agglomerates and various applications thereof.
Type:
Application
Filed:
July 31, 2007
Publication date:
February 5, 2009
Inventors:
Stephan Hausmanns, Tillmann Dorr, Jorg Kowalczyk, Rainer Kliss, Tilo Poth, Badr Nfissi, Andre Schirlitz
Abstract: Compositions, methods and kits to be used as a lubricant and for treatment of a cavity pathology including joint pathology are provided. The composition comprises therapeutically effective amounts of at least one bioactive agent, such as magnesium compound, at least one lubricating agent, such as hyaluronic acid, and at least one cell membrane repairing agent, such as polyethylene glycol. The components of these compositions may be administered by a direct application, an application through a cannula, an intra-articular injection, as a flush fluid during an arthroscopy of the affected area, as a post-arthroscopy injection, or as part of a lavage of the area affected by the intra-articular pathology. In addition, the composition of the present invention may be administered to the patient from a pump or a depot.
Type:
Application
Filed:
August 3, 2007
Publication date:
February 5, 2009
Inventors:
Susan J. Drapeau, Josee Roy, Daniel Andrew Shimko